All In Biotech

Drug Trial Radar · NCT00951496

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,560

Actual

Start

Aug 11, 2009

Primary completion

Jan 11, 2016

Study completion Jan 11, 2016

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Aug 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bevacizumab together with intravenous chemotherapy is more effective than giving bevacizumab together with intraperitoneal chemotherapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Conditions

  • Fallopian Tube Clear Cell Adenocarcinoma
  • Fallopian Tube Endometrioid Adenocarcinoma
  • Fallopian Tube Mucinous Adenocarcinoma
  • Fallopian Tube Serous Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fallopian Tube Undifferentiated Carcinoma
  • Malignant Ovarian Brenner Tumor
  • Ovarian Clear Cell Adenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Mucinous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Ovarian Serous Adenocarcinoma
  • Ovarian Transitional Cell Carcinoma
  • Ovarian Undifferentiated Carcinoma
  • Primary Peritoneal Clear Cell Adenocarcinoma
  • Primary Peritoneal Endometrioid Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma
  • Primary Peritoneal Transitional Cell Carcinoma
  • Primary Peritoneal Undifferentiated Carcinoma
  • Stage II Fallopian Tube Cancer AJCC v6 and v7
  • Stage II Ovarian Cancer AJCC v6 and v7
  • Stage IIA Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIA Ovarian Cancer AJCC V6 and v7
  • Stage IIB Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIB Ovarian Cancer AJCC v6 and v7
  • Stage IIC Fallopian Tube Cancer AJCC v6 and v7
  • Stage IIC Ovarian Cancer AJCC v6 and v7
  • Stage III Ovarian Cancer AJCC v6 and v7
  • Stage III Primary Peritoneal Cancer AJCC v7
  • Stage IIIA Ovarian Cancer AJCC v6 and v7
  • Stage IIIA Primary Peritoneal Cancer AJCC v7
  • Stage IIIB Ovarian Cancer AJCC v6 and v7
  • Stage IIIB Primary Peritoneal Cancer AJCC v7
  • Stage IIIC Ovarian Cancer AJCC v6 and v7
  • Stage IIIC Primary Peritoneal Cancer AJCC v7
  • Stage IV Fallopian Tube Cancer AJCC v6 and v7
  • Stage IV Ovarian Cancer AJCC v6 and v7
  • Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

  • BevacizumabBiological

    Given IV

  • CarboplatinDrug

    Given IV

  • CarboplatinDrug

    Given IP

  • CisplatinDrug

    Given IP

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • PaclitaxelDrug

    Given IP

  • Quality-of-Life AssessmentOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression-free SurvivalTime frame: Progression-free survival is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.

Locations

503 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Saint Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • PCR Oncology

    Arroyo Grande, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Marin General Hospital

    Greenbrae, California

  • Long Beach Memorial Medical Center-Todd Cancer Institute

    Long Beach, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Saint Joseph Hospital - Orange

    Orange, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • University of California San Diego

    San Diego, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • UCSF Medical Center-Mount Zion

    San Francisco, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • John Muir Medical Center-Walnut Creek

    Walnut Creek, California

  • Colorado Gynecologic Oncology Group

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • University of Colorado

    Denver, Colorado

  • Rocky Mountain Gynecologic Oncology PC

    Englewood, Colorado

  • Danbury Hospital

    Danbury, Connecticut

  • Hartford Hospital

    Hartford, Connecticut

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • Stamford Hospital/Bennett Cancer Center

    Stamford, Connecticut

Showing 40 of 503 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.